Enoblituzumab, previously known as TJ-271 or MGA271, represents an novel therapeutic targeting CD33, a antigen found predominantly on cancer cells. The agent operates as a two-pronged construct, at once attaching to https://mattiezzqj652091.pointblog.net/enoblituzumab-a-deep-dive-into-tj-271-and-mga271-92614277